SIGLEC1 and neoplasm: To test if the vaccination strategy targeting protein and peptide to CD169 could result in T cell responses strong enough to suppress established tumors, mice with a visible tumor (average tumor size of 30 mm3) were treated 7 days after tumor inoculation.